Comparison of Enoxaparin 40 mg Versus 60 mg Dosage for Venous Thromboprophylaxis in Patients Undergoing Bariatric Surgery: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230117004

Enrollment

Registered

2023-01-17

Start date

2020-05-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism (VTE) venous thromboembolism prophylaxis bariatric surgery morbid obesity enoxaparin anti-factor Xa level

Interventions

Enoxaparin 40 mg subcutaneously 12 hrs before surgery,Enoxaparin 60 mg subcutaneously 12 hrs before surgery

Experimental Drug,Experimental Drug

Enoxaparin 40 mg, Enoxaparin 60 mg

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: age 15 to 60 years, BMI greater than 32.5 kg/m2 with one of the comorbid diseases such as diabetes mellitus, cardiac disease, hypertension, and obstructive sleep apnea, or BMI greater than 37.5 kg/m2 with or without any comorbidity.

Exclusion criteria

Exclusion criteria: patients with a history of VTE or using anticoagulants and patients with severe medical conditions that are contraindicated for the operation.

Design outcomes

Primary

Measure	Time frame
Anti-factor Xa levels 4 hrs, 12 hrs after administration IU/ml	—

Secondary

Measure	Time frame
DVT 30-days postoperation Duplex ultraosonography	—

Countries

Thailand

Contacts

Public ContactPattharasai Kachornvitaya

Faculty of Medicine, Chulalongkorn University

pk_first17@hotmail.com0890354746

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026